Anti-inflammatory Small Drug as Adjunctive Therapy to Improve Glucometabolic Variables in Obese, Insulin-Resistant Type 2 Diabetic Patients

 描述(由申请人提供)：个体白细胞群在2型糖尿病(T2D)中的作用和免疫代谢总体上代表了更好地理解T2D病因的知识的重要缺口。新出现的证据表明，某些白细胞群是T2D相关炎症的重要纽带。这项新颖和创新的临床试验将测试一种白细胞选择性抗炎小药物作为辅助治疗在改善肥胖、胰岛素抵抗的2型糖尿病患者胰岛素敏感性方面的效果。这项试验还提供了一个首创的机会，以更好地了解特定的白细胞在2型糖尿病中的作用。该药物的临床情况表明，它的耐受性很好，几乎没有副作用，而且存在着间接测量其体内活性的简单方法。

 DESCRIPTION (provided by applicant): The role of individual leukocyte populations in type 2 diabetes (T2D) and immunometabolism in general represent important gaps in knowledge to better understand the etiopathogenesis of T2D. Emerging evidence indicates that certain leukocyte populations serve as an important nexus of T2D-associated inflammation. This novel and innovative clinical trial will test the efficacy of a leukocyte-selective anti-inflammatory small drug as adjunctive therapy in improving insulin sensitivity in obese, insulin-resistant type 2 diabetic subjects. This trial also offers a first-in-kind opportunity to better understand the role of specific leukocyte populations in type 2 diabetes. The drug’s clinical profile suggests that it will be well-tolerated with few, if any, side effects, and the existence of simple methods that can indirectly measure its activity in vivo.